Evidence map›Paper›PMID 30497423›Full record

ArticleBMC cancer2018

The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.

Mosche Pompsch, Julia Vogel, Fabian Classen, Philip Kranz, George Iliakis, Helena Riffkin, Ulf Brockmeier, Eric Metzen

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Clinical Significance of NUDT1 (MTH1) Across Cancer Types.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
  5. Iranian journal of public health · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mosche PompschInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
Julia VogelInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
Fabian ClassenInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
Philip KranzInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
George IliakisInstitut für Medizinische Strahlenbiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
Helena RiffkinInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
Ulf BrockmeierInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany.
Eric MetzenInstitut für Physiologie, Universität Duisburg-Essen, Hufelandstraße 55, D45122, Essen, Germany. Eric.Metzen@uni-due.de.ORCID http://orcid.org/0000-0002-2740-3219
University of Duisburg-Essen · DE

Funding

Deutsche Forschungsgemeinschaft GRK1739
6 · The paper itself

Abstract

backgroundThe nudix family member enzyme MutT homologue-1 (MTH1) hydrolyses the oxidized nucleotides 8-oxo-dGTP and 2-hydroxy-dATP and thus prevents the incorporation of damaged nucleotides into nuclear and mitochondrial DNA. Therefore MTH1 was proposed to protect cancer cells from oxidative DNA lesions and subsequent cell death. We investigated whether the bona fide MTH1 inhibitor TH588 affects responses of cultured colorectal tumor cells to ionizing radiation (IR) in normoxia and in moderate or severe hypoxia.

methodsTH588 was tested in cell viability and survival assays (tetrazolium dye (MTT), propidium iodide staining, caspase-3 activity, and colony formation assays (CFA)) in colorectal carcinoma cells (HCT116 and SW480) in combination with IR in normoxia and in hypoxia. Additionally, MTH1 was targeted by lentiviral shRNA expression. Human umbilical vein endothelial cells (HUVEC) were assessed in MTT assays.

resultsIn all cell lines tested, TH588 dose-dependently impaired cell survival. In CFAs, TH588 and IR effects on carcinoma cells were additive in normoxia and in hypoxia. Using 3 different shRNAs, the lentiviral approach was detrimental to SW480, but not to HCT116.

conclusionsTH588 has cytotoxic effects on transformed and untransformed cells and synergizes with IR in normoxia and in hypoxia. TH588 toxicity is not fully explained by MTH1 inhibition as HCT116 were unaffected by lentiviral suppression of MTH1 expression. TH588 should be explored further because it has radiosensitizing effects in hypoxia.

Indexed as

Radiation, IonizingApoptosisCell Line, TumorCell SurvivalColorectal NeoplasmsDNA Repair EnzymesDose-Response Relationship, DrugHEK293 CellsHumansHypoxiaOxidative StressPhosphoric Monoester HydrolasesPyrimidinesRadiation-Sensitizing AgentsRadiation Tolerance8-oxodGTPaseDNA Repair EnzymesPhosphoric Monoester HydrolasesPyrimidinesRadiation-Sensitizing AgentsTH588 compound8-oxo-GuanosinDNA damage repairMutT homologue-1Oxygen

Identifiers

PMID30497423
PMCPMC6267833
OpenAlexW2902798769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.